Drakenterprises
CardiologyDiabetesFamily MedicineEmergencyOrthopaedicsOtolaryngologyOncologyCross-cutting

Not clinical advice. Clinical Evidence is a current-awareness feed. It is not a clinical decision-support system, not medical advice, and not a substitute for clinical judgment, institutional protocols, or the original sources. Full text, NCCN recommendations, and Cochrane review bodies are not reproduced here.

All trials

TrialNCT06537609

A Platform Trial for Gram Negative Bloodstream Infections

Status
RECRUITING
Phase
NA
Last update posted
09/04/2026
Start
04/24/2024
Sponsor
Sunnybrook Health Sciences Centre
Specialties
emergency, cross-cutting

Conditions: Gram-negative Bacteremia

Brief summary

BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance. The initial vanguard pilot RCT (NCT05893147) started on 29 August 2023 and has successfully completed the pilot phase on 24-Apr-2024. All patients enrolled in the vanguard phase are part of the main platform trial.

Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.

Clinical Evidence